# Primmune Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/primmune-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.primmunerx.com
- Total disclosed funding: $47M
- Latest round: Series B (Jan 26, 2026)
- Investors on record: 7

## About

Primmune Therapeutics, Inc. is a biotechnology company focused on developing novel therapies that activate plasmacytoid dendritic cells to combat cancer and viral diseases, leveraging the TLR7 pathway for innovative treatment solutions.Founded in 2017 and headquartered in Carlsbad, US, Primmune Therapeutics specializes in therapeutic solutions targeting the immune response against cancers associated with viral infections. The founders, Jim Appleman and Paulo Rangel, established the firm to advance oncology treatments. In January 2026, Primmune Therapeutics, Inc. raised USD 8.6 million in series B funding from Oberland Capital, Bioqube Ventures, and Samsara BioCapital. Primmune Therapeutics, Inc. specializes in the development of innovative therapies targeting the activation of plasmacytoid dendritic cells (pDCs) via the toll-like receptor 7 (TLR7) pathway. Its lead clinical candidate, PRTX007, is a tuned TLR7 agonist designed for oral administration. This product uniquely stimulates a systemic immune response characterized by the production of Type I and III interferons without triggering the production of pro-inflammatory cytokines like IL-6, TNFa, or IL-1ß. The primary focus of Primmune's offerings is to address cancers associated with viral infections, particularly HPV-related oropharyngeal cancers and hepatocellular carcinoma. Primmune's solutions target healthcare providers and institutions involved in cancer treatment in the U.S. and are positioned to enter clinical trials rapidly for effective patient care in these therapeutic areas.Primmune Therapeutics operates within a revenue model structured around partnerships and clinical trial agreements with healthcare institutions and research organizations. Revenue generation is anticipated through collaborations with pharmaceutical companies and potential licensing agreements for PRTX007 and other TLR7 agonists. The company’s transaction structure involves direct interactions with clinical research entities and healthcare providers, focusing on trials and assessments that can lead to regulatory approvals for its products. As Primmune advances towards clinical trials, the structure of its financial engagements may include milestone payments associated with the development and commercialization of its lead candidate, thereby fostering a robust pipeline supported by strategic partnerships in the oncology sector. The company will use the January 2026 funding to support clinical development of PRTX007 and start a Phase 2 study in melanoma patients.

## Funding rounds

- Series B, Jan 26, 2026, $8.6M — Oberland Capital, Samsara BioCapital, Bioqube Ventures
- Series A, Jan 12, 2021, $4M — Bioqube Ventures
- Series A, Oct 27, 2020, $27M — Polaris Partners, CAM Capital, Oberland Capital, BioBrit, Samsara BioCapital, BioRock Ventures
- Seed, Mar 2, 2020, $7M — CAM Capital, BioBrit, BioRock Ventures

## Investors

- CAM Capital — Seed, Series A
- BioBrit — Seed, Series A
- BioRock Ventures (https://capitalatlas.ai/funds/biorock-ventures) — Seed, Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Oberland Capital — Series A, Series B
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B
- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Series A, Series B